Tebentafusp

Phase 3Recruiting

0 views this week 0 watching⚡ Active

Interest: 41/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Uveal Melanoma

Conditions

Uveal Melanoma

Trial Timeline

Nov 11, 2024 → Nov 1, 2032

NCT ID

NCT06246149

About Tebentafusp

Tebentafusp is a phase 3 stage product being developed by Immunocore for Uveal Melanoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06246149. Target conditions include Uveal Melanoma.

What happened to similar drugs?

0 of 1 similar drugs in Uveal Melanoma were approved

Approved (0) Terminated (0) Active (1)

🔄DarovasertibIDEAYA BiosciencesPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04960891	Pre-clinical	Active	—	—	Uveal Melanoma
NCT06070012	Phase 2	Recruiting	Aug 18, 2025	Sep 30, 2030	Uveal Melanoma
NCT06627244	Phase 2	Recruiting	Feb 14, 2025	Feb 17, 2031	Metastatic Uveal Melanoma
NCT06246149	Phase 3	Recruiting	Nov 11, 2024	Nov 1, 2032	Uveal Melanoma
NCT05315258	Phase 2	Active	Jul 25, 2022	Jun 30, 2027	Melanoma (Skin)

Competing Products

20 competing products in Uveal Melanoma

See all competitors

Product	Company	Stage	Hype Score
Pembrolizumab + Lenvatinib	Eisai	Phase 2	39
Selumetinib, 100mg + Selumetinib, 125mg + Selumetinib, 150mg + Selumetinib, 175mg + Selumetinib, 200mg + Selumetinib, 225mg	AstraZeneca	Phase 1	29
Pembrolizumab + Entinostat	Merck	Phase 2	35
Pembrolizumab + Olaparib	Merck	Phase 2	42
Pembrolizumab 25 MG/1 ML Intravenous Solution	Merck	Phase 2	39
AEB071	Novartis	Phase 1	29
LXS196 + LXS196 and HDM201	Novartis	Phase 1	21
DYP688	Novartis	Phase 1/2	36
RAD001 (Everolimus) and Pasireotide (SOM230) LAR	Novartis	Phase 2	35
ranibizumab + triamcinolone acetonide	Novartis	Phase 2/3	34
Crizotinib	Pfizer	Phase 2	35
Dacarbazine + Sunitinib	Pfizer	Phase 2	35
AEB071 + MEK162	Pfizer	Phase 1/2	24
Binimetinib + Belinostat	Pfizer	Phase 2	39
Ipilimumab + Nivolumab	Bristol Myers Squibb	Phase 1	29
Nivolumab + Relatlimab	Bristol Myers Squibb	Phase 2	35
ipilimumab + Nivolumab	Bristol Myers Squibb	Phase 2	35
ZIV-Aflibercept + Cemiplimab	Sanofi	Phase 2	42
Ziv-Aflibercept	Regeneron Pharmaceuticals	Phase 2	27
XmAb®23104 + Yervoy® (ipilimumab)	ICON plc.	Phase 1	26